Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. (\u201cEnable\u201d), a healthcare innovation company developing and manufacturing the enFuse\u00ae On-Body Delivery System, today announced a strategic partnership naming Aptar Digital Health as Enable\u2019s preferred digital health partner for the enFuse\u00ae system. This digital solution will be designed to guide patients and caregivers throughout the injection process and help support engagement before, during, and after administration.<\/p>\n
Through this partnership, Aptar Digital Health<\/a> will deliver a companion digital solution for Enable Injections<\/a>\u2019 enFuse\u00ae system designed to enhance the patient experience and support adherence-related programs. Key features of the solution may include treatment data recording, onboarding and training modules, injection guidance, patient-reported outcomes and symptom tracking – helping to empower patients and caregivers with greater confidence and control over the treatment process.<\/p>\n Built on a flexible and scalable architecture, the companion digital solution will be deployed alongside the enFuse\u00ae system, enabling pharmaceutical partners to extend the value of their therapies beyond delivery. Designed to evolve across the drug development lifecycle, the digital solution may support use cases from clinical trials through commercialization, aligned with development and launch strategies.<\/p>\n Adherence data and patient reported outcomes will be captured remotely, securely stored and made available through analytics dashboards that generate actionable insights intended to support clinical development, launch readiness and real-world use. The modular, program-specific design will allow pharmaceutical partners to integrate digital components into their clinical or commercial programs based on their needs. By combining device-generated data with patient reported insights, the digital solution will help drive more informed decisions grounded in real-world usage.<\/p>\n \u201cThis collaboration seeks to enhance the treatment experience of patients beyond the moment of injection,\u201d said Michael D. Hooven, Chairman and CEO of Enable Injections. \u201cTogether, we will combine innovative drug delivery with digital support tools. This can help patients remain engaged in their therapy and enable healthcare providers to better understand and support each patient\u2019s journey.\u201d<\/p>\n \u201cWe are excited to partner with Enable Injections to help bring the next generation of drug delivery solutions to life,\u201d said Damien McKeon, SVP Strategic Partnerships, Aptar Digital Health. \u201cLarge-volume biologic therapies are increasingly used to treat complex chronic conditions. They often require long-term adherence to achieve optimal outcomes. Digital solutions supporting treatment tracking and patient engagement can help address common adherence challenges associated with self-administration.\u201d<\/p>\n